APA

Hendriks H. R., Pizao P. E., Berger D. P., Kooistra K. L., Bibby M. C., Boven E., Dreef-van der Meulen H. C., Henrar R. E., Fiebig H. H. & Double J. A. (19930607). EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. : European journal of cancer (Oxford, England : 1990).

Chicago

Hendriks H R, Pizao P E, Berger D P, Kooistra K L, Bibby M C, Boven E, Dreef-van der Meulen H C, Henrar R E, Fiebig H H and Double J A. 19930607. EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. : European journal of cancer (Oxford, England : 1990).

Harvard

Hendriks H. R., Pizao P. E., Berger D. P., Kooistra K. L., Bibby M. C., Boven E., Dreef-van der Meulen H. C., Henrar R. E., Fiebig H. H. and Double J. A. (19930607). EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. : European journal of cancer (Oxford, England : 1990).

MLA

Hendriks H R, Pizao P E, Berger D P, Kooistra K L, Bibby M C, Boven E, Dreef-van der Meulen H C, Henrar R E, Fiebig H H and Double J A. EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. : European journal of cancer (Oxford, England : 1990). 19930607.